🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

PersonGen BioTherapeutics (Suzhou) clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with PersonGen BioTherapeutics (Suzhou) as lead sponsor. Synced 26 Sep 2026
12Current trials
7Recruiting now
4Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

PersonGen BioTherapeutics (Suzhou) is the lead sponsor of 12 current clinical trials in our China register. 7 are recruiting patients now. The most common phase is Phase EARLY_PHASE1. The drugs named most often in its trials are LV009, UTAA91 and Cyclophosphamide. The most-studied condition is Hematolymphoid Malignancies.

ClinicalTrials.gov trials by status

  • Recruiting758%
  • Not yet open542%

Trials by phase

  • Phase EARLY_PHASE1650%
  • Phase 1325%
  • Not applicable217%
  • Phase 218%
01

Clinical trials sponsored by PersonGen BioTherapeutics (Suzhou)

12 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic Malignancies
NCT07338604 · ClinicalTrials.gov ↗ · Hematolymphoid Malignancies
Phase EARLY_PHASE1 Recruiting 2025-12 China
Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies
NCT07284927 · ClinicalTrials.gov ↗ · Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia
Drug: LV009
Phase 1 Recruiting 2025-12 China
PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
NCT07188610 · ClinicalTrials.gov ↗ · CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma
Phase 2 Recruiting 2025-09 China
TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma
NCT05562024 · ClinicalTrials.gov ↗ · B7-H3-positive Relapsed/ Refractory Neuroblastoma
Phase 1 Recruiting 2022-12 China
UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.
NCT06092047 · ClinicalTrials.gov ↗ · CD19-positive Relapsed or Refractory B-cell Malignancies
Phase EARLY_PHASE1 Recruiting 2023-10 China
UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
NCT06279026 · ClinicalTrials.gov ↗ · Relapsed/Refractory Multiple Myeloma
Not applicable Recruiting 2024-04 China
Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies
NCT07312630 · ClinicalTrials.gov ↗ · Non-Hodgkin Lymphoma (NHL), Acute Lymphoblastic Leukemia (ALL), Adult
Drug: LV009
Phase EARLY_PHASE1 Recruiting 2025-09 China
Clinical Study on the Treatment of Refractory Rheumatoid Arthritis With UTAA91 Injection
NCT06982547 · ClinicalTrials.gov ↗ · Rheumatoid Arthritis (RA)
Drug: UTAA91
Phase EARLY_PHASE1 Not yet open 2025-06 China
Single-arm, Open-label, Dose-escalating Phase I Clinical Study of PA3-17 Injection in Children and Adolescents With Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
NCT07623681 · ClinicalTrials.gov ↗ · CD7+ T-ALL/LBL
Phase 1 Not yet open 2026-06 China
Clinical Study on the Treatment of Systemic Sclerosis With UTAA91 Injection.
NCT06982534 · ClinicalTrials.gov ↗ · Systemic Sclerosis (SSc)
Phase EARLY_PHASE1 Not yet open 2025-06 China
Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
NCT06970951 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus, Rheumatoid Arthritis, Dry Syndrome
Drug: UTAA91
Phase EARLY_PHASE1 Not yet open 2025-05 China
Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases
NCT06871644 · ClinicalTrials.gov ↗ · Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria
Not applicable Not yet open 2025-03 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in PersonGen BioTherapeutics (Suzhou) trials

4 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in PersonGen BioTherapeutics (Suzhou) trials

17 conditions
Hematolymphoid Malignancies1Rheumatoid Arthritis (RA)1Non-Hodgkin Lymphoma1Acute Lymphoblastic Leukemia1CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma1CD7+ T-ALL/LBL1Systemic Sclerosis (SSc)1B7-H3-positive Relapsed/ Refractory Neuroblastoma1CD19-positive Relapsed or Refractory B-cell Malignancies1Relapsed/Refractory Multiple Myeloma1Non-Hodgkin Lymphoma (NHL)1Acute Lymphoblastic Leukemia (ALL), Adult1Systemic Lupus Erythematosus1Rheumatoid Arthritis1Dry Syndrome1Idiopathic Inflammatory Myopathies1Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China127

A trial with sites in more than one country appears in each of those registers.

05

Questions about PersonGen BioTherapeutics (Suzhou) trials

How many clinical trials does PersonGen BioTherapeutics (Suzhou) sponsor?

PersonGen BioTherapeutics (Suzhou) is the lead sponsor of 12 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are PersonGen BioTherapeutics (Suzhou) trials recruiting?

Yes. 7 of its 12 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is PersonGen BioTherapeutics (Suzhou) testing?

Its current trials name 4 drugs and biologicals as interventions. The most frequent are LV009 (2), UTAA91 (2), Cyclophosphamide (1) and Fludarabine (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.